risk is probably dependent on the country where the device could...

risk is probably dependent on the country where the device could be sold , I believe the side airway technology is patented by Oventus for the USA jurisdiction , (there is a presentation showing patents/patents pending ) so little risk in the USA, probably different story in China if Oventus went there

Bigger risk I feel is if large pharma or a medical device company buys into the company and tries to derail it , before the company can realise its potential .
I doubt if a corporate raider could take it over as directors have a blocking stake , but seen enough shenanigans with other high potential stocks of retail investors being screwed by funds coming in then lending the stock for shorting and getting board positions to derail the company. This latest placement to funds/large SIs hurt my confidence in the corporate governance,/Board market intelligence here , placement should have been made to retail investors first , who's interests are completely in line with management .